Login / Signup

Development of Chimeric Molecules That Degrade the Estrogen Receptor Using Decoy Oligonucleotide Ligands.

Miyako NaganumaNobumichi OhokaGenichiro TsujiHaruna TsujimuraKenji MatsunoTakao InoueMikihiko NaitoYosuke Demizu
Published in: ACS medicinal chemistry letters (2021)
Targeted protein degradation using chimeric small molecules, such as proteolysis-targeting chimeras (PROTACs) and specific and nongenetic inhibitors of apoptosis protein (IAP)-dependent protein erasers (SNIPERs), has attracted attention as a method for degrading intracellular target proteins via the ubiquitin-proteasome system (UPS). These chimeric molecules target a variety of proteins using small molecules that can bind to the proteins. However, it is difficult to develop such degraders in the absence of suitable small-molecule ligands for the target proteins, such as for transcription factors (TFs). Therefore, we constructed the chimeric molecule LCL-ER(dec) , which consists of a decoy oligonucleotide that can bind to estrogen receptor α (ERα) and an IAP ligand, LCL161 (LCL), in a click reaction. LCL-ER(dec) was found to selectively degrade ERα via the UPS. These findings will be applicable to the development of other oligonucleotide-type degraders that target different TFs.
Keyphrases
  • estrogen receptor
  • cell therapy
  • small molecule
  • protein protein
  • transcription factor
  • cancer therapy
  • amino acid
  • endoplasmic reticulum stress
  • cell death
  • bone marrow
  • electron transfer